FilingReader Intelligence
MicroPort CardioFlow forecasts 83% net loss reduction
August 7, 2025 at 03:01 PM UTC•By FilingReader AI
MicroPort CardioFlow Medtech Corporation expects its net loss for the first half of 2025 to be no more than 10m yuan, an 83% reduction from the same period in 2024.
The improvement is attributed to over 200% growth in overseas revenue from VitaFlow Liberty and commercialization of AnchorMan in China and Europe.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2160•Hong Kong Exchange
News Alerts
Get instant email alerts when MicroPort CardioFlow Medtech Corporation publishes news
Free account required • Unsubscribe anytime